Ardsley, New York-based biopharmaceutical firm Acorda Therapeutics revealed new information derived from clinical and preclinical studies of tozadenant at the recent 2017 International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Vancouver, British Columbia.
Acorda is evaluating the formulation for its potential ability to reduce what practitioners refer to as “OFF time” in patients with Parkinson’s disease, referring to specific time periods when individuals experience resurgence of symptoms such as increased motor function fluctuation.
“OFF is cited by people with Parkinson’s as one of the most challenging aspects of their disease to manage,” Dr. Burkhard Blank, Acorda’s chief medical officer, said. “Tozadenant represents a potential first-in-class treatment for Parkinson’s in the U.S. that is being studied to reduce overall daily OFF time.”
Data offered at the MDS conference comprised three findings, summarized in titled abstracts: “Associating patient impression of improvement with efficacy endpoints in Parkinson’s disease: A post-hoc analysis of a tozadenant study;” “Tozadenant Phase 3 study (TOZ-PD) in Parkinson's disease patients with motor fluctuations: baseline characteristics;” and “Efficacy of tozadenant in animal models of non-motor symptoms of Parkinson's disease.”
Acorda anticipates results from a current Phase 3 clinical trial of the medication in early 2018. Spokespersons noted that the company also began a long-term open-label safety study this year.
Acorda develops therapies to revitalize function of those living with neurological disorders, including multiple sclerosis as well as Parkinson’s disease.